PT - JOURNAL ARTICLE AU - Shapira, Guy AU - Patalon, Tal AU - Gazit, Sivan AU - Shomron, Noam TI - Immunosuppression as a hub for SARS-CoV-2 mutational drift AID - 10.1101/2022.06.09.22276203 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.09.22276203 4099 - http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276203.short 4100 - http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276203.full AB - Newly emerging SARS-CoV-2 variants of concern (VOCs) play a major role in the persistence of the coronavirus disease 2019 (COVID-19) pandemic. While these VOCs are characterized by extraordinary evolutionary leaps and evasion from previously acquired immunity, their origins remain mostly unknown. In this study, we paired electronic health records of individuals infected with SARS-CoV-2 to viral whole-genome sequences, to assess effects of host clinical parameters and immunity on the intra-host evolution of SARS-CoV-2. We found small, albeit significant differences in SARS-CoV-2 intra-host diversity, which depended on host parameters such as vaccination status and smoking. Viral genomes showed a significant difference in the early course of disease in only one of 31 immunosuppressed patients, a recently vaccinated woman aged in her 70s. We highlight the unusually mutated viral genome obtained from this woman, which harbored near-complete truncating of the accessory protein ORF3a. Our findings suggest only minor influence of host parameters on the SARS-CoV-2 intra-host evolutionary rate and trajectory, with even the majority of immunosuppressed persons carrying fairly unremarkable viral genomes. We hypothesize that major evolutionary steps, such as those observed in VOCs, are rare occurrences, even among immunodeficient hosts.HighlightsIntra-host viral diversity is modestly affected by host clinical parameters, such as vaccination status and smoking.The emergence and fixation of high-impact SARS-CoV-2 mutations in immunosuppressed hosts are rare, and not exclusive to patients with prolonged viral shedding.We identified a rare stop-gain mutation, leading to near-complete truncating of ORF3a, in an immunosuppressed woman recently vaccinated against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the following: Horizon 2020 Research and Innovation Framework Programme, PSYPGx; The Edmond J. Safra Center for Bioinformatics at Tel Aviv University; The Koret_UC Berkeley_Tel Aviv University Initiative in Computational Biology and Bioinformatics; The QBI/UCSF_Tel Aviv University joint Initiative in Computational Biology and Drug Discovery; Tel Aviv University Richard Eimert Research Fund on Solid Tumors; Collaborative clinical Bioinformatics research of the Edmond J. Safra Center for Bioinformatics and Faculty of Medicine at Tel Aviv University; Israeli Ministry of Science and Technology, Israeli_Russia; Kodesz Institute for Technologies in Healthcare; Tel Aviv University Healthy Longevity Research Center; Tel Aviv University Innovation Laboratories (TILabs).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Maccabi Healthcare Services (MHS) Institutional Review Board. Due to its retrospective design, informed consent was waived, and all identifying details of the participants were removed before computational analysis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe electronic health records used in this study are confidential and protected by law. Other data used in this study is currently private.